SAN FRANCISCO – With positive Phase III data in hand from European trials and more due this year from U.S. pivotal studies, Kythera Biopharmaceuticals Inc. offered attendees of the J.P. Morgan Healthcare Conference the company's game plan for earnings as "a new entrant into the established market of facial injectables," said Keith Leonard, co-founder, president and CEO.